Traws Pharma, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
TRAW Nasdaq 2830 www.trawspharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Traws Pharma, Inc.

Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients - Jan 13th, 2026 5:00 am
TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors - Dec 22nd, 2025 6:01 am
Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients - Dec 17th, 2025 4:00 am
Traws Pharma Reports Third Quarter 2025 Results and Business Highlights - Nov 13th, 2025 5:00 am
ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials - Oct 30th, 2025 10:00 am
Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19. - Oct 22nd, 2025 4:40 pm
Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025 - Oct 14th, 2025 5:00 am
Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives - Oct 6th, 2025 5:00 am
Annovis Appoints Mark Guerin as Chief Financial Officer - Sep 25th, 2025 5:30 am
Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025 - Aug 18th, 2025 5:00 am
Traws Pharma Reports Second Quarter 2025 Results and Business Highlights - Aug 14th, 2025 5:00 am
Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025 - Aug 8th, 2025 5:00 am
Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions - Jun 30th, 2025 4:30 am
Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib - Jun 3rd, 2025 5:00 am
Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness - May 27th, 2025 6:00 am
Traws Pharma Reports First Quarter 2025 Results and Business Highlights - May 15th, 2025 5:00 am
Traws Pharma Reports Full Year 2024 Results and Business Highlights - Mar 31st, 2025 7:00 am
Traws Pharma Announces Management Updates - Mar 28th, 2025 2:30 pm
Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET - Mar 26th, 2025 5:30 am
Traws Pharma’s COVID-19 Candidate, Ratutrelvir, Presented at ICAR - Mar 25th, 2025 5:30 am